Senseye, Inc. Company Profile

Background

Overview

Senseye, Inc., founded in 2015 and headquartered in Austin, Texas, is a pioneering digital health company specializing in objective mental health diagnostics. The company leverages advanced computer vision and artificial intelligence (AI) technologies to analyze ocular biomarkers, enabling clinicians to assess and monitor mental health conditions with unprecedented accuracy and efficiency. Senseye's mission is to empower individuals and healthcare providers with fast, non-invasive tools for mental health assessment, starting with Post-Traumatic Stress Disorder (PTSD).

Mission and Vision

Senseye envisions a world where mental health conditions are as visible and treatable as physical ailments. By transforming the diagnostic process into an objective, rapid, and accessible procedure, the company aims to enhance personalized care and improve patient outcomes across various mental health disorders.

Industry Significance

The mental health crisis is a global challenge, with millions affected by conditions such as PTSD, anxiety, depression, and addiction. Traditional diagnostic methods often rely on subjective self-reports, leading to potential misdiagnoses and delayed treatments. Senseye's innovative approach addresses these challenges by providing objective, real-time assessments through smartphone-based diagnostics, thereby revolutionizing mental health care delivery.

Key Strategic Focus

Core Objectives

• Objective Diagnostics: Develop and deploy non-invasive, objective diagnostic tools for mental health conditions, starting with PTSD.

• Personalized Care: Enable clinicians to establish clear baselines and track patient outcomes over time, facilitating tailored treatment plans.

• Accessibility: Utilize everyday technology, such as smartphones, to make mental health assessments widely accessible without the need for specialized equipment.

Areas of Specialization

• Mental Health Diagnostics: Focus on conditions like PTSD, anxiety disorders, depression, and addiction.

• Ocular Biomarkers: Employ eye physiology metrics, including pupil dynamics and eye movement, as indicators of mental health status.

• AI and Computer Vision: Leverage advanced machine learning algorithms and computer vision techniques to analyze ocular data.

Key Technologies Utilized

• Computer Vision: Capture and analyze high-resolution video footage of the eye using standard smartphone cameras.

• Artificial Intelligence: Apply deep learning models to interpret ocular data and extract meaningful biomarkers.

• Mobile Platforms: Develop smartphone applications to facilitate easy and widespread deployment of diagnostic tools.

Primary Markets Targeted

• Healthcare Providers: Clinics, hospitals, and mental health professionals seeking efficient diagnostic tools.

• Telehealth Services: Platforms offering remote mental health assessments and consultations.

• Military and Defense: Organizations requiring rapid and accurate mental health evaluations for personnel.

Financials and Funding

Funding History

Senseye has secured multiple funding rounds to support its growth and technological development:

• Venture Round (September 2023): Raised $3.81 million, with investments from Capital Factory and Whatif Ventures.

• Strategic Investment (September 2025): Received a strategic investment from Topcon Healthcare, Inc., a global leader in digital health and ocular data solutions, to advance mental health diagnostics through ocular biomarkers.

Total Funds Raised

As of February 2026, Senseye has raised approximately $4.68 million in total funding.

Utilization of Capital

The capital raised is primarily allocated towards:

• Product Development: Enhancing diagnostic algorithms and expanding the range of mental health conditions addressed.

• Clinical Trials: Conducting studies to validate the efficacy and accuracy of diagnostic tools.

• Market Expansion: Scaling operations to reach a broader audience, including international markets.

Pipeline Development

Key Pipeline Candidates

• PTSD Diagnostic Tool: A smartphone-based application that analyzes ocular biomarkers to assess PTSD severity.

• Major Depressive Disorder (MDD) Diagnostic Tool: An extension of the platform to detect and monitor MDD through eye physiology metrics.

• Generalized Anxiety Disorder (GAD) Diagnostic Tool: A diagnostic module focused on identifying GAD using ocular biomarkers.

Stages of Development

• PTSD Diagnostic Tool: Completed initial pilot studies with promising results; preparing for larger-scale clinical trials.

• MDD and GAD Diagnostic Tools: In the research and development phase, with plans for pilot studies in the near future.

Target Conditions

• PTSD: Affecting millions globally, characterized by symptoms such as flashbacks, nightmares, and severe anxiety.

• MDD: A mood disorder leading to persistent feelings of sadness and loss of interest.

• GAD: Excessive, uncontrollable worry about various aspects of life.

Anticipated Milestones

• Clinical Trials: Initiation of large-scale trials for PTSD diagnostic tool in Q3 2026.

• Regulatory Approvals: Seeking FDA clearance for PTSD diagnostic tool by Q4 2026.

• Market Launch: Commercial release of PTSD diagnostic tool in early 2027.

Technological Platform and Innovation

Proprietary Technologies

• Ocular System for Mental Health Diagnostics: A patented system that uses eye physiology to infer mental health conditions.

• Emotional Intelligence Engine (EIE): A platform that analyzes ocular data to assess cognitive and emotional states.

Significant Scientific Methods

• Deep Learning Algorithms: Utilized to process and interpret complex ocular data.

• Signal Extraction Techniques: Methods developed to extract meaningful biomarkers from eye movements and pupil dynamics.

AI-Driven Capabilities

• Real-Time Analysis: Processing ocular data in real-time to provide immediate feedback.

• Scalability: Deploying diagnostic tools across various platforms and settings without the need for specialized equipment.

Leadership Team

Key Executives

• David Zakariaie: Founder & CEO. David has a background in computational neuroscience and has led the development of Senseye's innovative diagnostic platform.

• Simon Woods: President & COO. Simon brings extensive experience in healthcare operations and has been instrumental in scaling Senseye's business operations.

• Brad Strasser: VP of Clinical, Quality & Regulatory. Brad oversees clinical trials, quality assurance, and regulatory compliance, ensuring the company's products meet industry standards.

• Caitlin Limonciello, PhD: Director of Research. Caitlin leads the research team, focusing on advancing the scientific methodologies underlying Senseye's diagnostic tools.

Market Context and Competitor Profile

Market Dynamics

The digital mental health diagnostics market is growing rapidly, fueled by increased awareness of mental health issues and the demand for accessible, objective assessment tools. Advances in AI and computer vision are fostering innovative solutions that offer alternatives to conventional diagnostic methods.

Competitor Overview

• H2O.ai: Provides AI-driven solutions applicable in healthcare among other industries.

• Actility: Specializes in IoT solutions for predictive maintenance, primarily in industrial sectors.

• Exosite: Offers IoT platforms focusing on industrial applications, including predictive maintenance.

Strategic Collaborations

Topcon Healthcare, Inc. made a strategic investment in Senseye in September 2025 to support the advancement of mental health diagnostics through ocular biomarkers, enhancing Senseye's technological capabilities and market position.

Operational Differentiators

Senseye offers a unique, non-invasive, smartphone-based diagnostic platform that delivers real-time, objective mental health assessments. This accessibility and efficiency distinguish Senseye in the digital mental health diagnostics landscape.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Product Expansion: Further development of tools for additional mental health conditions, including bipolar disorder and schizophrenia.

• Global Expansion: Extending market presence internationally, tailoring products for diverse cultural and regulatory frameworks.

• Healthcare Integration: Partnering with electronic health record (EHR) providers to seamlessly incorporate diagnostic tools into healthcare workflows.

Future Business Directions

Senseye aims to solidify its position as a global leader in mental health diagnostics by continuing product innovation and broadening its offerings to increase both accessibility and effectiveness of mental health care worldwide.